非ホジキンリンパ腫治療薬の世界市場 2023-2027

当レポートでは非ホジキンリンパ腫治療薬の市場規模は、2022年から2027年の間に54億2,751万米ドル、予測期間中のCAGRは8.14%で成長すると予測しています。

当レポートでは、非ホジキンリンパ腫治療薬市場について、全体的な分析、市場規模と予測、動向、成長促進要因、課題、さらに約25のベンダーを網羅したベンダー分析を行っています。

現在の市場動向と促進要因、市場環境全体に関する最新の分析を提供しています。市場は、最近の承認と強力なパイプライン、高齢者人口の増加、特効薬の指定によって牽引されています。

本調査では、今後数年間の非ホジキンリンパ腫治療薬市場の成長を促進する主要な理由の一つとして、研究助成金と資金提供を挙げています。また、がんに対する意識の高まりや患者支援プログラム、診療報酬の増加は、市場の大きな需要につながるでしょう。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2022
• 市場の見通し：2022-2027年の予測

第4章 市場規模実績

• 世界の非ホジキンリンパ腫治療薬市場2017～2021年
• 治療セグメント分析2017-2021
• 流通チャネルセグメント分析2017-2021
• 地域セグメント分析2017-2021
• 国セグメント分析2017-2021

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 流通チャネル別市場セグメンテーション

• マーケット・セグメント
• 流通チャネル別比較
• 病院薬局 - 市場規模と予測 2022-2027
• 小売薬局 - 市場規模と予測 2022-2027
• オンライン薬局 - 市場規模と予測 2022-2027
• その他 - 市場規模と予測 2022-2027
• 流通チャネル別の市場機会

第7章 治療法別市場セグメンテーション

• マーケット・セグメント
• 治療法別比較
• 免疫療法 - 市場規模と予測 2022-2027
• 標的療法 - 市場規模と予測 2022-2027
• 化学療法 - 市場規模と予測 2022-2027
• 治療法別の市場機会

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米 - 市場規模と予測 2022-2027
• 欧州 - 市場規模と予測 2022-2027
• アジア - 市場規模と予測 2022-2027
• その他の地域（ROW） - 市場規模と予測 2022-2027
• 米国 - 市場規模と予測 2022-2027
• 英国 - 市場規模と予測 2022-2027
• ドイツ - 市場規模と予測 2022-2027
• 中国 - 市場規模と予測 2022-2027
• カナダ - 市場規模と予測 2022-2027
• 地域情勢別の市場機会

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• AstraZeneca Plc
• BeiGene Ltd.
• Biogen Inc.
• Bristol Myers Squibb Co.
• Eisai Co. Ltd.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Johnson and Johnson Services Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Seagen Inc.
• Spectrum Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibits6: Executive Summary - Chart on Market Segmentation by Therapy
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits18: Historic Market Size - Data Table on Global non-hodgkin lymphoma therapeutics market 2017 - 2021 ($ million)
• Exhibits19: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
• Exhibits20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2022 and 2027
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
• Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
• Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
• Exhibits29: Chart on Market condition - Five forces 2022 and 2027
• Exhibits30: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibits31: Data Table on Distribution Channel - Market share 2022-2027 (%)
• Exhibits32: Chart on Comparison by Distribution Channel
• Exhibits33: Data Table on Comparison by Distribution Channel
• Exhibits34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibits35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibits36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibits39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibits40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibits43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibits44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibits46: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibits47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibits48: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibits49: Data Table on Others - Year-over-year growth 2022-2027 (%)
• Exhibits50: Market opportunity by Distribution Channel ($ million)
• Exhibits51: Chart on Therapy - Market share 2022-2027 (%)
• Exhibits52: Data Table on Therapy - Market share 2022-2027 (%)
• Exhibits53: Chart on Comparison by Therapy
• Exhibits54: Data Table on Comparison by Therapy
• Exhibits55: Chart on Immunotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibits56: Data Table on Immunotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibits57: Chart on Immunotherapy - Year-over-year growth 2022-2027 (%)
• Exhibits58: Data Table on Immunotherapy - Year-over-year growth 2022-2027 (%)
• Exhibits59: Chart on Targeted therapy - Market size and forecast 2022-2027 ($ million)
• Exhibits60: Data Table on Targeted therapy - Market size and forecast 2022-2027 ($ million)
• Exhibits61: Chart on Targeted therapy - Year-over-year growth 2022-2027 (%)
• Exhibits62: Data Table on Targeted therapy - Year-over-year growth 2022-2027 (%)
• Exhibits63: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibits64: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibits65: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
• Exhibits66: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
• Exhibits67: Market opportunity by Therapy ($ million)
• Exhibits68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits69: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits70: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits71: Chart on Geographic comparison
• Exhibits72: Data Table on Geographic comparison
• Exhibits73: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits74: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits75: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibits76: Data Table on North America - Year-over-year growth 2022-2027 (%)
• Exhibits77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits79: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits80: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits81: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits82: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits83: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits84: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits85: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits86: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits87: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits88: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits89: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibits90: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibits91: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibits92: Data Table on US - Year-over-year growth 2022-2027 (%)
• Exhibits93: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits95: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibits96: Data Table on UK - Year-over-year growth 2022-2027 (%)
• Exhibits97: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits98: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits99: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits100: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits101: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibits102: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibits103: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibits104: Data Table on China - Year-over-year growth 2022-2027 (%)
• Exhibits105: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibits106: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibits107: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits108: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits109: Market opportunity By Geographical Landscape ($ million)
• Exhibits110: Impact of drivers and challenges in 2022 and 2027
• Exhibits111: Overview on Criticality of inputs and Factors of differentiation
• Exhibits112: Overview on factors of disruption
• Exhibits113: Impact of key risks on business
• Exhibits114: Vendors covered
• Exhibits115: Matrix on vendor position and classification
• Exhibits116: AstraZeneca Plc - Overview
• Exhibits117: AstraZeneca Plc - Product / Service
• Exhibits118: AstraZeneca Plc - Key news
• Exhibits119: AstraZeneca Plc - Key offerings
• Exhibits120: BeiGene Ltd. - Overview
• Exhibits121: BeiGene Ltd. - Business segments
• Exhibits122: BeiGene Ltd. - Key offerings
• Exhibits123: BeiGene Ltd. - Segment focus
• Exhibits124: Biogen Inc. - Overview
• Exhibits125: Biogen Inc. - Product / Service
• Exhibits126: Biogen Inc. - Key offerings
• Exhibits127: Bristol Myers Squibb Co. - Overview
• Exhibits128: Bristol Myers Squibb Co. - Product / Service
• Exhibits129: Bristol Myers Squibb Co. - Key news
• Exhibits130: Bristol Myers Squibb Co. - Key offerings
• Exhibits131: Eisai Co. Ltd. - Overview
• Exhibits132: Eisai Co. Ltd. - Business segments
• Exhibits133: Eisai Co. Ltd. - Key offerings
• Exhibits134: Eisai Co. Ltd. - Segment focus
• Exhibits135: F. Hoffmann La Roche Ltd. - Overview
• Exhibits136: F. Hoffmann La Roche Ltd. - Business segments
• Exhibits137: F. Hoffmann La Roche Ltd. - Key news
• Exhibits138: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibits139: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibits140: Gilead Sciences Inc. - Overview
• Exhibits141: Gilead Sciences Inc. - Product / Service
• Exhibits142: Gilead Sciences Inc. - Key news
• Exhibits143: Gilead Sciences Inc. - Key offerings
• Exhibits144: GlaxoSmithKline Plc - Overview
• Exhibits145: GlaxoSmithKline Plc - Business segments
• Exhibits146: GlaxoSmithKline Plc - Key offerings
• Exhibits147: GlaxoSmithKline Plc - Segment focus
• Exhibits148: Johnson and Johnson Services Inc. - Overview
• Exhibits149: Johnson and Johnson Services Inc. - Business segments
• Exhibits150: Johnson and Johnson Services Inc. - Key news
• Exhibits151: Johnson and Johnson Services Inc. - Key offerings
• Exhibits152: Johnson and Johnson Services Inc. - Segment focus
• Exhibits153: Merck KGaA - Overview
• Exhibits154: Merck KGaA - Business segments
• Exhibits155: Merck KGaA - Key news
• Exhibits156: Merck KGaA - Key offerings
• Exhibits157: Merck KGaA - Segment focus
• Exhibits158: Novartis AG - Overview
• Exhibits159: Novartis AG - Business segments
• Exhibits160: Novartis AG - Key offerings
• Exhibits161: Novartis AG - Segment focus
• Exhibits162: Pfizer Inc. - Overview
• Exhibits163: Pfizer Inc. - Product / Service
• Exhibits164: Pfizer Inc. - Key news
• Exhibits165: Pfizer Inc. - Key offerings
• Exhibits166: Seagen Inc. - Overview
• Exhibits167: Seagen Inc. - Product / Service
• Exhibits168: Seagen Inc. - Key offerings
• Exhibits169: Spectrum Pharmaceuticals Inc. - Overview
• Exhibits170: Spectrum Pharmaceuticals Inc. - Product / Service
• Exhibits171: Spectrum Pharmaceuticals Inc. - Key offerings
• Exhibits172: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibits173: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibits174: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibits175: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibits176: Teva Pharmaceutical Industries Ltd. - Segment focus
• Exhibits177: Inclusions checklist
• Exhibits178: Exclusions checklist
• Exhibits179: Currency conversion rates for US$
• Exhibits180: Research methodology
• Exhibits181: Validation techniques employed for market sizing
• Exhibits182: Information sources
• Exhibits183: List of abbreviations

Technavio has been monitoring the non-Hodgkin lymphoma therapeutics market and is forecast to grow by $5427.51 mn during 2022-2027, accelerating at a CAGR of 8.14% during the forecast period. Our report on the non-Hodgkin lymphoma therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by recent approvals and strong pipeline, growing geriatric population, and special drug designations.

Technavio's non-Hodgkin lymphoma therapeutics market is segmented as below:

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy
• Others

By Therapy

• Immunotherapy
• Targeted therapy
• Chemotherapy

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the research grants and funding as one of the prime reasons driving the non-Hodgkin lymphoma therapeutics market growth during the next few years. Also, growing awareness about cancer and increase in patient assistance programs and reimbursements will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the non-Hodgkin lymphoma therapeutics market covers the following areas:

• Non-Hodgkin lymphoma therapeutics market sizing
• Non-Hodgkin lymphoma therapeutics market forecast
• Non-Hodgkin lymphoma therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-Hodgkin lymphoma therapeutics market vendors that include AstraZeneca Plc, Baxter International Inc., Bayer AG, BeiGene Ltd., Biogen Inc., Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the non-Hodgkin lymphoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Therapy
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global non-hodgkin lymphoma therapeutics market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on Global non-hodgkin lymphoma therapeutics market 2017 - 2021 ($ million)
• 4.2 Therapy Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
• 4.3 Distribution channel Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

• 6.1 Market segments
• Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
• 6.2 Comparison by Distribution Channel
• Exhibit 32: Chart on Comparison by Distribution Channel
• Exhibit 33: Data Table on Comparison by Distribution Channel
• 6.3 Hospital pharmacy - Market size and forecast 2022-2027
• Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• 6.4 Retail pharmacy - Market size and forecast 2022-2027
• Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• 6.5 Online pharmacy - Market size and forecast 2022-2027
• Exhibit 42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)
• 6.6 Others - Market size and forecast 2022-2027
• Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
• 6.7 Market opportunity by Distribution Channel
• Exhibit 50: Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Therapy

• 7.1 Market segments
• Exhibit 51: Chart on Therapy - Market share 2022-2027 (%)
• Exhibit 52: Data Table on Therapy - Market share 2022-2027 (%)
• 7.2 Comparison by Therapy
• Exhibit 53: Chart on Comparison by Therapy
• Exhibit 54: Data Table on Comparison by Therapy
• 7.3 Immunotherapy - Market size and forecast 2022-2027
• Exhibit 55: Chart on Immunotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on Immunotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on Immunotherapy - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on Immunotherapy - Year-over-year growth 2022-2027 (%)
• 7.4 Targeted therapy - Market size and forecast 2022-2027
• Exhibit 59: Chart on Targeted therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 60: Data Table on Targeted therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Chart on Targeted therapy - Year-over-year growth 2022-2027 (%)
• Exhibit 62: Data Table on Targeted therapy - Year-over-year growth 2022-2027 (%)
• 7.5 Chemotherapy - Market size and forecast 2022-2027
• Exhibit 63: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 64: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
• Exhibit 66: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
• 7.6 Market opportunity by Therapy
• Exhibit 67: Market opportunity by Therapy ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 69: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibit 70: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 71: Chart on Geographic comparison
• Exhibit 72: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 73: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 81: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 85: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 89: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 UK - Market size and forecast 2022-2027
• Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
• 9.9 Germany - Market size and forecast 2022-2027
• Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.10 China - Market size and forecast 2022-2027
• Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)
• 9.11 Canada - Market size and forecast 2022-2027
• Exhibit 105: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 106: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 107: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 108: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 109: Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 110: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 111: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 112: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 113: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 114: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 115: Matrix on vendor position and classification
• 12.3 AstraZeneca Plc
• Exhibit 116: AstraZeneca Plc - Overview
• Exhibit 117: AstraZeneca Plc - Product / Service
• Exhibit 118: AstraZeneca Plc - Key news
• Exhibit 119: AstraZeneca Plc - Key offerings
• 12.4 BeiGene Ltd.
• Exhibit 120: BeiGene Ltd. - Overview
• Exhibit 121: BeiGene Ltd. - Business segments
• Exhibit 122: BeiGene Ltd. - Key offerings
• Exhibit 123: BeiGene Ltd. - Segment focus
• 12.5 Biogen Inc.
• Exhibit 124: Biogen Inc. - Overview
• Exhibit 125: Biogen Inc. - Product / Service
• Exhibit 126: Biogen Inc. - Key offerings
• 12.6 Bristol Myers Squibb Co.
• Exhibit 127: Bristol Myers Squibb Co. - Overview
• Exhibit 128: Bristol Myers Squibb Co. - Product / Service
• Exhibit 129: Bristol Myers Squibb Co. - Key news
• Exhibit 130: Bristol Myers Squibb Co. - Key offerings
• 12.7 Eisai Co. Ltd.
• Exhibit 131: Eisai Co. Ltd. - Overview
• Exhibit 132: Eisai Co. Ltd. - Business segments
• Exhibit 133: Eisai Co. Ltd. - Key offerings
• Exhibit 134: Eisai Co. Ltd. - Segment focus
• 12.8 F. Hoffmann La Roche Ltd.
• Exhibit 135: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 136: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 137: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 138: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 139: F. Hoffmann La Roche Ltd. - Segment focus
• 12.9 Gilead Sciences Inc.
• Exhibit 140: Gilead Sciences Inc. - Overview
• Exhibit 141: Gilead Sciences Inc. - Product / Service
• Exhibit 142: Gilead Sciences Inc. - Key news
• Exhibit 143: Gilead Sciences Inc. - Key offerings
• 12.10 GlaxoSmithKline Plc
• Exhibit 144: GlaxoSmithKline Plc - Overview
• Exhibit 145: GlaxoSmithKline Plc - Business segments
• Exhibit 146: GlaxoSmithKline Plc - Key offerings
• Exhibit 147: GlaxoSmithKline Plc - Segment focus
• 12.11 Johnson and Johnson Services Inc.
• Exhibit 148: Johnson and Johnson Services Inc. - Overview
• Exhibit 149: Johnson and Johnson Services Inc. - Business segments
• Exhibit 150: Johnson and Johnson Services Inc. - Key news
• Exhibit 151: Johnson and Johnson Services Inc. - Key offerings
• Exhibit 152: Johnson and Johnson Services Inc. - Segment focus
• 12.12 Merck KGaA
• Exhibit 153: Merck KGaA - Overview
• Exhibit 154: Merck KGaA - Business segments
• Exhibit 155: Merck KGaA - Key news
• Exhibit 156: Merck KGaA - Key offerings
• Exhibit 157: Merck KGaA - Segment focus
• 12.13 Novartis AG
• Exhibit 158: Novartis AG - Overview
• Exhibit 159: Novartis AG - Business segments
• Exhibit 160: Novartis AG - Key offerings
• Exhibit 161: Novartis AG - Segment focus
• 12.14 Pfizer Inc.
• Exhibit 162: Pfizer Inc. - Overview
• Exhibit 163: Pfizer Inc. - Product / Service
• Exhibit 164: Pfizer Inc. - Key news
• Exhibit 165: Pfizer Inc. - Key offerings
• 12.15 Seagen Inc.
• Exhibit 166: Seagen Inc. - Overview
• Exhibit 167: Seagen Inc. - Product / Service
• Exhibit 168: Seagen Inc. - Key offerings
• 12.16 Spectrum Pharmaceuticals Inc.
• Exhibit 169: Spectrum Pharmaceuticals Inc. - Overview
• Exhibit 170: Spectrum Pharmaceuticals Inc. - Product / Service
• Exhibit 171: Spectrum Pharmaceuticals Inc. - Key offerings
• 12.17 Teva Pharmaceutical Industries Ltd.
• Exhibit 172: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 173: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 174: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 176: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 177: Inclusions checklist
• Exhibit 178: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 179: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 180: Research methodology
• Exhibit 181: Validation techniques employed for market sizing
• Exhibit 182: Information sources
• 13.5 List of abbreviations
• Exhibit 183: List of abbreviations